New lung cancer treatment shrinks some tumors: study
Monday 07 June 2010
A new experimental drug helps shrink tumors in lung cancer patients with a specific form of genetic alteration, according to results from a clinical trial unveiled Saturday.
The Pfizer Inc. drug crizotinib shrank tumors in patients with advanced non-small cell lung cancer (NSCLC) with a specific gene alteration of an enzyme implicated in cancer cell growth, known as anaplastic lymphoma kinase, or ALK.
According to Pfizer, around 10,000 people in the United States are affected by a lung cancer with this particular genetic mutation.
About 90 percent of the 82 participants in the small-scale Phase I clinical trial responded positively, and more than half - 57 percent - saw their tumors shrink after eight weeks, said lead author Yung-Jue Bang, a physician at Seoul National University College of Medicine.
Researchers had only expected about 10 percent of the patients, many of whom had already received three or more prior treatments, to respond to the treatment.
"These results are quite dramatic, and represent an important improvement over what we would see with standard chemotherapy for patients with metastatic disease," Bang told a news conference.
Most of the NSCLC patients were former smokers or never smoked. The median duration of treatment was approximately six months.
Crizotinib, which is taken orally, works by inhibiting the ALK enzyme. About one in 20 lung cancer patients in the United States are estimated to be diagnosed with ALK-positive NSCLC each year.
The genetic variation targeted by crizotinib affects about five percent of lung cancer patients. Each year, 12 million new cases of lung cancer are diagnosed worldwide and nearly eight million people die from the disease.
The study was presented at the American Society of Clinical Oncology conference, which is being held in Chicago this weekend.
Pfizer has begun a late-stage, or Phase III, trial to determine whether crizotinib improves the survival rate of ALK-positive lung cancer patients compared to standard chemotherapy treatment.
Life & Style blogs
Company breaks open Apple Watch to discover what it says is 'planned obsolescence'
KickAssTorrents down: biggest file-sharing site moves to .cr domain after takedowns
Gisele Bundchen celebrates 20-year catwalk career with naked Vogue cover
The confessions of men who ordered mail-order brides
Protein World 'Beach body ready' advert: Mass demonstration in Hyde Park planned against 'body-shaming' weight loss advertisements
- 1 Avengers: Age of Ultron: Nearly 700 German cinemas refuse to show movie
- 2 Man cooked alive with 12,000 pounds of tuna
- 3 X Factor in crisis as numbers of people auditioning plummets
- 4 General Election 2015: Stephen Hawking says he will vote Labour
- 5 Baltimore riots: Furious mother marches her son home live on TV
£23000 - £25000 per annum: Recruitment Genius: This firm of accountants based ...
£30000 - £38000 per annum: Recruitment Genius: They are a financial services c...
£30000 - £32000 per annum + car allowance and on call: Ashdown Group: A succes...
£15000 - £17000 per annum: Recruitment Genius: Well established small company ...